Replies to post #429457 on NorthWest Biotherapeutics Inc (NWBO)

[lrdpdx77]

Too latte for that to happen. It's been tried (not saying by Merck) but NWBO survived. We are too close to TLD/Publication, commencement of increased manufacturing and generation of significantly higher revenue. As well, NWBO has solidified their patent portfolio.

[X Master]

Merck might kill the name but they would change their process to incorporate DCVax and call it Keytruda Plus. They would also have a brand new patent that has an extended period. That alone is worth Billions if not Trillions of dollars for all solid tumors and a new standard of care that they own.

[biosectinvestor]

That’s nice David. We are starting to see a them with you David…

[X Master]

They might kill the name but they need the patent extension. Thus they will get a new and improved Keytruda.

[ahp123]

they did not get it for free, as I remember they paid over 3B, but you are right that, it was far below their MC .. think it was over 6 B ... it was many years ago so dont remember the exact numbers but think it was in that ballpark ..
But your general point is even more important .. people here think that BP, as for example Merck. are our friends who "lend out” their experts to help us with BLA etc. and thereby helping us to
increase our value ... LOL
and funny enough, they still hold on to the narrative that there are great evil forces out there trying to take us down…. And that might be right .but people here cant have it both ways

[biosectinvestor]

Not likely. That is not how acquisitions work for large companies. A direct competitor might want to see the company struggle and to take its IP. But a large drug company that may be seeking a later relationship, either partnership or acquisition wants to see the product validated before they acquire any interest in it. They are risk averse. They have plenty of income and resources, they are looking for products that they can transform into gold, and an early acquisition doesn’t suit them if it is not validated yet. But once validated, then it is something that they can calculate the value for if they own it and use it for instance as a way to create a stronger product line and combination therapy route in Oncology, it can create a dominance that lasts for decades.